SCHEMBL6184482

SCHEMBL6184482

CC(CCNC(=O)c1ccc(-c2csc(-c3cccnc3)n2)cc1)CC(=O)NCC#N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 5/20 0.49
TP53 P04637 2/20 0.49
NPC1 O15118 4/20 0.48
POLB P06746 2/20 0.47
CYP19A1 P11511 3/20 0.45
AXL P30530 1/20 0.45
PBRM1 Q86U86 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
THRB P10828 1/20 0.45
KDM4E B2RXH2 4/20 0.44
HPGD P15428 2/20 0.44
EIF4E P06730 1/20 0.43
ADRB3 P13945 1/20 0.43
AGTR1 P30556 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183464 0.91 NPC1 (0.48) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6182002 0.87 RAB9A (0.51) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6183518 0.86 RAB9A (0.46) RAB9AALDH1A1MEN1KMT2ANPC1
SCHEMBL6183157 0.83 KDM4E (0.60) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7450325 0.83 ALDH1A1 (0.47) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7452860 0.83 KDM4E (0.60) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6183646 0.81 PARP1 (0.52) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6179951 0.80 RAB9A (0.51) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6183920 0.80 NPC1 (0.45) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6184479 0.80 CTSB (0.62) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed
EP-1161415-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2001068645-A2 N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-09-20 WO disclosed
WO-2000055126-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 RAB9A 2240/4885SMN1; SMN2 3462/4885ALDH1A1 4049/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 RAB9A 2240/4885SMN1; SMN2 3462/4885ALDH1A1 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.